Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 3Small Cell Lung Carcinoma 1Non-Erosive Reflux Disease 1Neoplasms 1Lung Neoplasms 1Helicobacter Infections 1Gastrointestinal Hemorrhage 1Gastroesophageal Reflux 1Gastritis, Atrophic 1Dyspepsia 1Carcinoma, Non-Small-Cell Lung 1Barrett Esophagus 1Adenocarcinoma 1Acrocephalosyndactylia 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × Rabeprazole × Clear all
NCT07076914 2025-07-22

PPI-PROTECT

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Not yet recruiting
58 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡